Home
TRVI

TRVI

Trevi Therapeutics Inc.

as of 12-15-2025 3:38pm EST

$12.62

$0.14

-1.14%

Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Chart Type:

Time Range:

Founded:	2011	Country:	United States
Employees:	N/A	City:	NEW HAVEN
Market Cap:	1.4B	IPO Year:	2019
Target Price:	$20.59	AVG Volume (30 days):	2.4M
Analyst Decision:	Strong Buy	Number of Analysts:	11
Dividend Yield:	N/A	Dividend Payout Frequency:	N/A
EPS:	-0.37	EPS Growth:	N/A
52 Week Low/High:	$3.43 - $14.39	Next Earning Date:	11-13-2025
Revenue:	N/A	Revenue Growth:	N/A
Revenue Growth (this year):	N/A	Revenue Growth (next year):	N/A

AI-Powered TRVI Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated a day ago

AI Recommendation

hold

Model Accuracy: 70.67%

70.67%

Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

View Full TRVI Forecast & Prediction with Hourly Data

Compare TRVI vs Leading Stocks

See how TRVI stacks up against similar companies in the market

Share on Social Networks:

Tools & Resources

Enhance your trading experience with our free tools

Free TRVI Stock Widget

Embed our interactive stock ticker widget on your website for real-time updates.

Free Tool

Stock Alerts on Telegram

Get instant notifications, market insights, and expert analysis delivered to your phone.

Live Updates

Disclaimer

The information presented on this page, "TRVI Trevi Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.